Loading company…
PolyPid develops localized drug delivery therapies intended to improve surgical outcomes.
PolyPid is a clinical-stage biopharmaceutical company developing therapies for localized medication release over days to months, targeting infection, pain, inflammation, and cancer. Its D-PLEX100 and D-PLEX1000 candidates are intended to prevent surgical site infections and address bone infections. The company is based in Petah Tikva, Israel, and raised USD 16.2 million in PIPE funding from DAFNA Capital Management and Rosalind Advisors in January 2024.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in